VRX

Valeant was trading at 10x revenue despite making a loss, with adjusted accounting claiming a 55% margin. The company was involved in unethical practices, and despite being well-funded, it was expecte

Valeant Pharmaceuticals is viewed as a potential zero by some investors due to its aggressive financial engineering and reliance on acquisitions. The company has a high likelihood of facing bankruptcy

Ackman discusses the challenges of GAAP accounting for companies like Valeant, suggesting that while it has been acquisitive, the focus should be on understanding the economic earnings rather than jus

Ackman is open to hearing contrary views on Valeant, indicating that he is aware of the significant debate surrounding the stock and is willing to consider opposing perspectives.

Valeant is interesting because they are looking to acquire Allergan, which has been a natural target for them. Even if the acquisition doesn't go through, Valeant is likely to buy something else, and